SG11201600167SA - Targeted modified il-1 family members - Google Patents
Targeted modified il-1 family membersInfo
- Publication number
- SG11201600167SA SG11201600167SA SG11201600167SA SG11201600167SA SG11201600167SA SG 11201600167S A SG11201600167S A SG 11201600167SA SG 11201600167S A SG11201600167S A SG 11201600167SA SG 11201600167S A SG11201600167S A SG 11201600167SA SG 11201600167S A SG11201600167S A SG 11201600167SA
- Authority
- SG
- Singapore
- Prior art keywords
- family members
- targeted modified
- targeted
- modified
- family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600167SA true SG11201600167SA (en) | 2016-02-26 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600167SA SG11201600167SA (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (es) |
| EP (1) | EP3022226B1 (es) |
| JP (1) | JP6475713B2 (es) |
| KR (1) | KR102275090B1 (es) |
| CN (1) | CN105612180B (es) |
| AU (1) | AU2014292377B2 (es) |
| BR (1) | BR112016001128A2 (es) |
| CA (1) | CA2918518C (es) |
| DK (1) | DK3022226T3 (es) |
| ES (1) | ES2714504T3 (es) |
| IL (1) | IL243466B (es) |
| MX (1) | MX370348B (es) |
| SG (1) | SG11201600167SA (es) |
| WO (1) | WO2015007542A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| WO2017075533A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
| EP3426278B1 (en) | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
| EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
| JP7105200B2 (ja) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | 標的突然変異体インターフェロン－ベータおよびその使用 |
| ES2917000T3 (es) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Interferón-gamma mutante diana y usos del mismo |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
| WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| WO2019032663A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
| EP3733716A4 (en) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE |
| US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE103932T1 (de) | 1989-08-22 | 1994-04-15 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001029870A1 (en) * | 1999-10-21 | 2001-04-26 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US20110038865A1 (en) * | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| JP5764127B2 (ja) * | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
| CN102497885A (zh) * | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| KR102037541B1 (ko) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| JP6416628B2 (ja) | 2012-01-20 | 2018-10-31 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 標的変異体αヘリックスバンドルサイトカイン |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
-
2014
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en active Application Filing
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active IP Right Grant
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX370348B (es) | 2019-12-10 |
| US20160152730A1 (en) | 2016-06-02 |
| EP3022226B1 (en) | 2018-12-05 |
| US20180186894A1 (en) | 2018-07-05 |
| JP2016527221A (ja) | 2016-09-08 |
| US20200255545A1 (en) | 2020-08-13 |
| DK3022226T3 (en) | 2019-03-25 |
| CA2918518C (en) | 2022-08-16 |
| BR112016001128A2 (pt) | 2018-01-23 |
| AU2014292377A1 (en) | 2016-02-04 |
| KR20160108293A (ko) | 2016-09-19 |
| MX2016000723A (es) | 2016-12-20 |
| CA2918518A1 (en) | 2015-01-22 |
| ES2714504T3 (es) | 2019-05-28 |
| EP3022226A1 (en) | 2016-05-25 |
| AU2014292377B2 (en) | 2019-08-01 |
| IL243466B (en) | 2019-11-28 |
| US20190202934A1 (en) | 2019-07-04 |
| WO2015007542A1 (en) | 2015-01-22 |
| US20230235086A1 (en) | 2023-07-27 |
| KR102275090B1 (ko) | 2021-07-09 |
| CN105612180B (zh) | 2019-11-12 |
| US9932409B2 (en) | 2018-04-03 |
| CN105612180A (zh) | 2016-05-25 |
| JP6475713B2 (ja) | 2019-02-27 |
| IL243466A0 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243466A0 (en) | Members of the il–1 family are modified targets | |
| IL243509B (en) | Modified target tnf family members | |
| SG11201510297QA (en) | Targeted integration | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3613453T3 (da) | Fordamper | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| DK2956698T5 (da) | Bindestrimler | |
| DK3052081T3 (da) | Pastil | |
| DK2946640T3 (da) | Langmuir-probe | |
| DK3071227T3 (da) | Fiskevaccine | |
| ITRM20130708A1 (it) | Letto famiglia | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| DK2833043T3 (da) | Ventilindretning | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK2981168T3 (da) | Laminitiskile | |
| DK3086679T3 (da) | Sportssko | |
| ES1078715Y (es) | Mosquitera | |
| DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
| BR112016000501A2 (pt) | Nalador | |
| UY4316S (es) | Diseño celosías | |
| UA26491S (uk) | Сидіння | |
| ITMN20130009A1 (it) | Raccordo antigoccia: | |
| ES1100380Y (es) | Trompo |